	107002027
	NCT03599765
Title	Systemic Therapy With or Without Local Consolidative Therapy in Treating Patients With Oligometastatic Solid Tumor
Phase	Phase 2
Date Added	2018-07-26
Location	Arizona, United States Arkansas, United States
	Hawaii, United States
	Michigan, United States New Jersey, United States
	Ohio, United States
	Texas, United States
Prior IO Allowed	Yes
CRC-directed	No
Status	Active, not recruiting
Drugs	
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT03577665
Title	Curative Proton Beam Therapy for Patients With Liver Metastasis of Colorectal Cancer
Phase	Not Applicable
Date Added	2018-07-05
Location	Korea, Republic of
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	
-	MSI-H/ MMRd, MSS/ MMRp
Tags	
NCT ID	NCT03568058
NCT ID	NCT03568058
NCT ID Title	NCT03568058 Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers
NCT ID Title Phase	NCT03568058 Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers Phase 1
NCT ID Title Phase Date Added	NCT03568058 Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers Phase 1 2018-06-26
NCT ID Title Phase Date Added Location	NCT03568058 Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers Phase 1 2018-06-26 California, United States
NCT ID Title Phase Date Added Location Prior IO Allowed	NCT03568058 Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers Phase 1 2018-06-26 California, United States Yes
NCT ID Title Phase Date Added Location Prior IO Allowed CRC-directed	NCT03568058 Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers Phase 1 2018-06-26 California, United States Yes No
NCT ID Title Phase Date Added Location Prior IO Allowed CRC-directed Status	NCT03568058 Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers Phase 1 2018-06-26 California, United States Yes No Active, not recruiting
NCT ID Title Phase Date Added Location Prior IO Allowed CRC-directed Status Drugs	NCT03568058 Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers Phase 1 2018-06-26 California, United States Yes No Active, not recruiting Pembrolizumab, personalized vaccine, Keytruda
NCT ID Title Phase Date Added Location Prior IO Allowed CRC-directed Status Drugs Tags	NCT03568058 Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers Phase 1 2018-06-26 California, United States Yes No Active, not recruiting Pembrolizumab, personalized vaccine, Keytruda MSS/ MMRp
NCT ID Title Phase Date Added Location Prior IO Allowed CRC-directed Status Drugs Tags	NCT03568058 Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers Phase 1 2018-06-26 California, United States Yes No Active, not recruiting Pembrolizumab, personalized vaccine, Keytruda MSS/ MMRp NCT03566355
NCT ID Title Phase Date Added Location Prior IO Allowed CRC-directed Status Drugs Tags NCT ID Title	NCT03568058 Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers Phase 1 2018-06-26 California, United States Yes No Active, not recruiting Pembrolizumab, personalized vaccine, Keytruda MSS/ MMRp NCT03566355 Curative Proton Beam Therapy for Patients With Lung Metastasis of Colorectal Cancer
NCT ID Title Phase Date Added Location Prior IO Allowed CRC-directed Status Drugs Tags NCT ID Title Phase	NCT03568058 Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers Phase 1 2018-06-26 California, United States Yes No Active, not recruiting Pembrolizumab, personalized vaccine, Keytruda MSS/ MMRp NCT03566355 Curative Proton Beam Therapy for Patients With Lung Metastasis of Colorectal Cancer Not Applicable
NCT ID Title Phase Date Added Location Prior IO Allowed CRC-directed Status Drugs Tags NCT ID Title Phase Date Added	NCT03568058         Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers         Phase 1         2018-06-26         California, United States         Yes         No         Active, not recruiting         Pembrolizumab, personalized vaccine, Keytruda         MSS/ MMRp         NCT03566355         Curative Proton Beam Therapy for Patients With Lung Metastasis of Colorectal Cancer         Not Applicable         2018-06-25
NCT ID Title Phase Date Added Location Prior IO Allowed CRC-directed Status Drugs Tags NCT ID Title Phase Date Added Location	NCT03568058         Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers         Phase 1         2018-06-26         California, United States         Yes         No         Active, not recruiting         Pembrolizumab, personalized vaccine, Keytruda         MSS/ MMRp         NCT03566355         Curative Proton Beam Therapy for Patients With Lung Metastasis of Colorectal Cancer         Not Applicable         2018-06-25         Korea, Republic of
NCT ID Title Phase Date Added Location Prior IO Allowed CRC-directed Status Drugs Tags NCT ID Title Phase Date Added Location Prior IO Allowed	NCT03568058 Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers Phase 1 2018-06-26 California, United States Yes No Active, not recruiting Pembrolizumab, personalized vaccine, Keytruda MSS/ MMRp NCT03566355 Curative Proton Beam Therapy for Patients With Lung Metastasis of Colorectal Cancer Not Applicable 2018-06-25 Korea, Republic of Yes
NCT ID Title Phase Date Added Location Prior IO Allowed CRC-directed Status Drugs Tags NCT ID Title Phase Date Added Location Prior IO Allowed CRC-directed	NCT03568058 Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers Phase 1 2018-06-26 California, United States Yes No Active, not recruiting Pembrolizumab, personalized vaccine, Keytruda MSS/ MMRp NCT03566355 Curative Proton Beam Therapy for Patients With Lung Metastasis of Colorectal Cancer Not Applicable 2018-06-25 Korea, Republic of Yes
NCT ID Title Phase Date Added Location Prior IO Allowed CRC-directed Status Drugs Tags NCT ID Title Phase Date Added Location Prior IO Allowed CRC-directed Status	NCT03568058 Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers Phase 1 2018-06-26 California, United States Yes No Active, not recruiting Pembrolizumab, personalized vaccine, Keytruda MSS/ MMRp NCT03566355 Curative Proton Beam Therapy for Patients With Lung Metastasis of Colorectal Cancer Not Applicable 2018-06-25 Korea, Republic of Yes
NCT ID Title Phase Date Added Location Prior IO Allowed CRC-directed Status Drugs Tags NCT ID Title Phase Date Added Location Prior IO Allowed CRC-directed Status Drugs	NCT03568058 Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers Phase 1 2018-06-26 California, United States Yes No Active, not recruiting Pembrolizumab, personalized vaccine, Keytruda MSS/ MMRp NCT03566355 Curative Proton Beam Therapy for Patients With Lung Metastasis of Colorectal Cancer Not Applicable 2018-06-25 Korea, Republic of Yes Yes Recruiting

Title	A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC
Phase	Phase 2
Date Added	2018-06-06
Location	California, United States Florida, United States Kansas, United States New Jersey, United States Ohio, United States Oregon, United States
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Active, not recruiting
Drugs	FPV-CV301, mFOLFOX6, MVA-BN-CV301, Nivolumab
Tags	MSS/ MMRp
	NCT03545815
Title	Study of CRISPR-Cas9 Mediated PD-1 and TCR Gene-knocked Out Mesothelin-directed CAR-T Cells in Patients With
	Mesothelin Positive Multiple Solid Tumors.
Phase	Phase 1
Date Added	2018-06-04
Location	China
Prior IO Allowed	Yes
CRC-directed	No
Status	Recruiting
Drugs	anti-mesothelin CAR-T cells
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT03530397
NCT ID Title	NCT03530397 A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors
Title Phase Date Added	A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors Phase 1 2018-05-21
Title Phase	A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors Phase 1 2018-05-21 Michigan, United States New York, United States North Carolina, United States Rhode Island, United States Tennessee, United States Virginia, United States Australia France Italy Korea, Republic of Netherlands Portugal Spain
Title Phase Date Added	A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors Phase 1 2018-05-21 Michigan, United States New York, United States North Carolina, United States Rhode Island, United States Tennessee, United States Virginia, United States Virginia, United States Virginia, United States France Italy Korea, Republic of Netherlands Portugal
Title Phase Date Added Location	A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors Phase 1 2018-05-21 Michigan, United States New York, United States North Carolina, United States Rhode Island, United States Tennessee, United States Virginia, United States Australia France Italy Korea, Republic of Netherlands Portugal Spain Taiwan
Title Phase Date Added Location	A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors Phase 1 2018-05-21 Michigan, United States New York, United States North Carolina, United States Rhode Island, United States Tennessee, United States Virginia, United States Virginia, United States Australia France Italy Korea, Republic of Netherlands Portugal Spain Taiwan Yes
Title Phase Date Added Location Prior IO Allowed CRC-directed Status	A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors Phase 1 2018-05-21 Michigan, United States New York, United States North Carolina, United States Rhode Island, United States Tennessee, United States Tennessee, United States Yirginia, United States Australia France Italy Korea, Republic of Netherlands Portugal Spain Taiwan Yes No
Title Phase Date Added Location Prior IO Allowed CRC-directed	A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors Phase 1 2018-05-21 Michigan, United States New York, United States North Carolina, United States Rhode Island, United States Tennessee, United States Virginia, United States Virginia, United States Australia France Italy Korea, Republic of Netherlands Portugal Spain Taiwan Yes
Title Phase Date Added Location Prior IO Allowed CRC-directed Status Drugs Tags	A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors Phase 1 2018-05-21 Michigan, United States New York, United States North Carolina, United States Rhode Island, United States Tennessee, United States Virginia, United States Virginia, United States Vastralia France Italy Korea, Republic of Netherlands Portugal Spain Taiwan Yes No Active, not recruiting Carboplatin, MEDI5752, Pembrolizumab, Pemetrexed, Alimta, Imfinzi, Keytruda, Paraplatin MSI-H/ MMRd, MSS/ MMRp
Title Phase Date Added Location  Prior IO Allowed CRC-directed Status Drugs Tags NCT ID	A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors Phase 1 2018-05-21 Michigan, United States New York, United States North Carolina, United States Rhode Island, United States Tennessee, United States Virginia, United States Virginia, United States Virginia, United States Virginia, United States Vastralia France Italy Korea, Republic of Netherlands Portugal Spain Taiwan Yes No Active, not recruiting Carboplatin, MEDI5752, Pembrolizumab, Pemetrexed, Alimta, Imfinzi, Keytruda, Paraplatin MSI-H/ MMRd, MSS/ MMRp
Title Phase Date Added Location Prior IO Allowed CRC-directed Status Drugs Tags	A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors Phase 1 2018-05-21 Michigan, United States New York, United States North Carolina, United States Rhode Island, United States Tennessee, United States Virginia, United States Virginia, United States Vastralia France Italy Korea, Republic of Netherlands Portugal Spain Taiwan Yes No Active, not recruiting Carboplatin, MEDI5752, Pembrolizumab, Pemetrexed, Alimta, Imfinzi, Keytruda, Paraplatin MSI-H/ MMRd, MSS/ MMRp

Date Added	2018-05-09
Location	Italy
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	pembrolizumab (treatment), temozolomide (induction),, Keytruda, Temodar
Tags	MSS/ MMRp
NCT ID	NCT03502733
Title	Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma
Phase	Phase 1
Date Added	2018-04-19
Location	Maryland, United States Texas, United States
Prior IO Allowed	Yes
CRC-directed	No
Status	Active, not recruiting
Drugs	Copanlisib, Ipilimumab, Nivolumab, Aliqopa, Opdivo
Tags	MSS/ MMRp
NCT ID	NCT03494946
Title	Liver Transplantation Compared to Chemotherapy in Patients With ColoRectal Cancer
Phase	Not Applicable
Date Added	2018-04-11
Location	Norway
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	Chemotherapy
Tags	MSI-H/ MMRd, MSS/ MMRp